Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Down 15.9% in February

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the recipient of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 44,400 shares, a decrease of 15.9% from the January 31st total of 52,800 shares. Based on an average daily trading volume, of 3,390,000 shares, the days-to-cover ratio is presently 0.0 days.

Insider Buying and Selling

In related news, CFO Gordon Dunn purchased 122,221 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $0.45 per share, with a total value of $54,999.45. Following the completion of the transaction, the chief financial officer now owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. This trade represents a 423.55 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Denise P. Carter purchased 555,556 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $0.45 per share, for a total transaction of $250,000.20. Following the acquisition, the chief operating officer now owns 602,648 shares in the company, valued at $271,191.60. The trade was a 1,179.72 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 777,777 shares of company stock worth $350,000. 3.70% of the stock is owned by company insiders.

Institutional Trading of Quoin Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC purchased a new stake in Quoin Pharmaceuticals during the fourth quarter worth approximately $52,000. Boothbay Fund Management LLC purchased a new stake in Quoin Pharmaceuticals during the 4th quarter worth $53,000. Renaissance Technologies LLC increased its holdings in Quoin Pharmaceuticals by 244.1% in the 4th quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock valued at $87,000 after purchasing an additional 94,431 shares in the last quarter. Finally, Altium Capital Management LLC purchased a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $184,000. Institutional investors and hedge funds own 8.63% of the company’s stock.

Quoin Pharmaceuticals Trading Down 4.9 %

NASDAQ:QNRX traded down $0.02 on Thursday, hitting $0.31. 281,793 shares of the stock were exchanged, compared to its average volume of 2,278,447. The stock has a fifty day moving average of $0.44 and a 200-day moving average of $0.57. The stock has a market cap of $1.56 million, a PE ratio of -0.08 and a beta of 1.72. Quoin Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $1.58.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.